ID
Source
Brief title
Health condition
Dopamine, Learning, Working memory, Motivation, Mental effort
Sponsors and support
Donders Institute for Brain, Cognition and Behaviour - Centre for Cognitive Neuroimaging
Intervention
Outcome measures
Primary outcome
Effects of methylphenidate on behavioural performance on a battery of computerized tasks:
1. Social Learning (contrast of personal versus social learning)
2. Working memory performance
3-4. Motivational influences on instrumental behaviour (Pavlovian-instrumental transfer and motivational Go/Nogo tasks)
5. Demand selection task task (Biases towards easy/difficult conditions)
6. Probabilistic reversal learning (reinforcement sensitivity and behavioural flexibility)
Secondary outcome
Baseline personality questionnaires:
- Spielberger Trait Anxiety Inventory (Spielberger, 2010);
- Multidimensional Scale of Perceived Social Support (Martinez et al., 2010); (http://www.yorku.ca/rokada/psyctest/socsupp.pdf)
- Dominance scale (Kalma et al., 1993);
- Barratt Simplified Measure of Social Status (Martinez et al., 2010 -http://socialclassoncampus.blogspot.co.uk/2012/06/barratt-simplified-measure-of-social.html);
- The Beck Depression Inventory (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961);
- Positive and negative affect scale (Watson et al., 1988) • The BIS/BAS (Behavioural Inhibition Scale/Behavioural Activation (BIS/BAS) Scale (Carver & White, 1994);
- The Barratt Impulsiveness Scale (Patton, Stanford, & Barratt, 1995);
- Need for Cognition Scale (Cacioppo, Pettz, and Kao, 1984) B
Baseline assessment of executive function
- Listening span (Daneman and Carpenter, 1980);
- Digit Span (Wechsler 2008);
- Dutch Adult reading test (NLV - Schmand et al., 1991).
Methylphenidate-induced changes in mood and physiological measures
- Positive Affect Negative Affect (PANAS; Watson et al., 1988);
- Mood rating scale (Bond & Lader, 1974);
- Changes in blood pressure and heart rate;
- Medical symptoms visual analogue rating scale.
Study design
2 separate testing days for placebo and drug conditions. Total testing time 4-5 hrs, 1 week - 2 months apart, starting time within 90 mins of same time of day.
Intervention
Participants will twice complete a battery of computerized tests after administration of methylphenidate / placebo. On the day preceding testing, subjects will have to adhere to some simple restrictions with respect to medication, alcohol and drug intake.
Roshan Cools
Nijmegen
The Netherlands
roshan.cools@donders.ru.nl
Roshan Cools
Nijmegen
The Netherlands
roshan.cools@donders.ru.nl
Inclusion criteria
1. Healthy volunteers;
2. Age 18 - 45 years;
3. Normal or corrected-to-normal vision;
4. Normal uncorrected hearing;
5. Willingness and ability to give written informed consent and willingness and ability to understand the nature and content, to participate and to comply with the study requirements.
Exclusion criteria
1. History of / current
• psychiatric / neurological treatment
• neurological treatment
• endocrine treatment
• requent autonomic failure (e.g., vasovagal reflex syncope).
• clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, ocular or pulmonary disease
• epilepsy in adulthood (inclusion when no insult after 18 years of age, no current medication for epilepsy and no insult in the last five years)
• drug dependence (opiate, LSD, (meth)amphetamine, cocaine, solvents, or barbiturate) or alcohol dependence
• Diabetes
2. Suicidality
3. Medication use:
• MAO inhibitor, anaesthetic, anti-depressant or anti psychotic drugs within the week prior to the start of the study.
• psychotropic medication, or of recreational drugs over a period of 24 hours prior to each test session, and use of alcohol within the last 24 hours before each measurement.
• Regular use of corticosteroids.
4. Uncontrolled hypertension, defined as diastolic blood pressure at rest > 95 mmHg or systolic blood pressure at rest > 180 mmHg
5. Irregular sleep/wake rhythm (e.g., regular nightshifts or cross timeline travel).
6 .Possible pregnancy or breastfeeding
7. Lactose intolerance (placebo pill is a lactose product)
8. One first degree or two or more second degree family members with a history of sudden death or ventricular arrhythmia
9. First degree family member with schizophrenia or bipolar disorder
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4411 |
| NTR-old | NTR4653 |
| CCMO | NL47166.091.13 |
| OMON | NL-OMON26989 |